ArticleBoneKEy reports2014
Vitamin D endocrine system and osteoclasts.
Article in BoneKEy reports, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 54 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
54 citing papers in PubMed, 1 synthesis or guideline pooled it, 120 citations in OpenAlex.
- Adynamic bone disorder in chronic kidney disease: meta-analysis and narrative review of potential biomarkers as diagnosis and therapeutic targets.Renal failure · 2025Pooled it
- Trial
- Effects of collagen peptide supplementation on bone turnover, cytokine, and inflammatory markers in female distance runners: a randomized pilot study.Frontiers in nutrition · 2026Article
- The effect of probiotic baker's yeast on egg quality, tibia characteristics, and hepatic lipid peroxidation in laying hens.Scientific reports · 2025Article
- Bone Health in Paediatric Inflammatory Bowel Disease.Diagnostics (Basel, Switzerland) · 2025Review
- The unexplored relationship between spontaneous osteoclastogenesis and platelets in osteoporosis.Frontiers in medicine · 2025Article
- Modeling calcium and magnesium balance: Regulation by calciotropic hormones and adaptations under varying dietary intake.iScience · 2024Article
- Interaction between MARK3 (rs11623869), PLCB4 (rs6086746) and GEMIN2 (rs2277458) variants with bone mineral density and serum 25-hidroxivitamin D levels in Mexican Mestizo women.Frontiers in endocrinology · 2024Article
- The impact of vitamin D on clinical parameters and bone turnover biomarkers in ligature-induced periodontitis: An experimental study in rats.The Saudi dental journal · 2023Article
- The Capacity of Magnesium to Induce Osteoclast Differentiation Is Greatly Enhanced by the Presence of Zoledronate.Biology · 2023Article
- Osteoporosis and periodontal diseases - An update on their association and mechanistic links.Periodontology 2000 · 2022Review
- Galectin-3 Contributes to the Inhibitory Effect of lα,25-(OH)International journal of molecular sciences · 2021Article
- Jejunal transcriptomic profiling of two layer strains throughout the entire production period.Scientific reports · 2021Article
- Vitamin D and Rheumatic Diseases: A Review of Clinical Evidence.International journal of molecular sciences · 2021Review
- The effects of calcitonin on post-orthodontic relapse in rats.Clinical and experimental dental research · 2021Article
- Article
- The Effect of Anadara granosa Shell's-Stichopus hermanni Scaffold on CD44 and IL-10 Expression to Decrease Osteoclasts in Socket Healing.European journal of dentistry · 2021Article
- Possible Roles of Vitamin D in Bone Grafting.Cureus · 2021Review
- Vitamin K and D Supplementation and Bone Health in Chronic Kidney Disease-Apart or Together?Nutrients · 2021Review
- l-Cysteine and Vitamin D Co-Supplementation Alleviates Markers of Musculoskeletal Disorders in Vitamin D-Deficient High-Fat Diet-Fed Mice.Nutrients · 2020Article
Corrections and comments
- Erratum issuedUdagawa, Naoyuki [corrected to Udagawa, Nobuyuki]
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Vitamin D was discovered as an anti-rachitic agent preventing a failure in bone mineralization, but it is now established that the active form of vitamin D3 (1α,25(OH)2D3) induces bone resorption. Discovery of the receptor activator of nuclear factor -κB ligand (RANKL) uncovered the molecular mechanism by which 1α,25(OH)2D3 stimulates bone resorption. Treating osteoblastic cells with 1α,25(OH)2D3 stimulates RANKL expression, which in turn induces osteoclastogenesis. Nevertheless, active vitamin D compounds such as calcitriol (1α,25(OH)2D3), alfacalcidol (1α(OH)D3) and eldecalcitol (1α,25-dihydroxy-2β-(3-hydroxypropoxy) vitamin D3) have been used as therapeutic drugs for osteoporosis, as they increase bone mineral density (BMD) in osteoporotic patients. Paradoxically, the increase in BMD is caused by the suppression of bone resorption. Several studies have been performed to elucidate the mechanism by which active vitamin D compounds suppress bone resorption in vivo. Our study showed that daily administration of eldecalcitol to mice suppressed neither the number of osteoclast precursors in the bone marrow nor the number of osteoclasts formed in ex vivo cultures. Eldecalcitol administration suppressed RANKL expression in osteoblasts. This review discusses how the difference between in vitro and in vivo effects of active vitamin D compounds on bone resorption is induced.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.